文献速递炎症性肠病消化道肿瘤与早癌

有乳腺癌病史的炎症性肠病患者发生新发癌症的风险:一项多中心队列研究

Risk of Incident Cancer in Patients With Inflammatory Bowel Disease With Prior Breast Cancer: A Multicenter Cohort Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-11-05

该多中心回顾性研究纳入207例有乳腺癌病史的炎症性肠病患者,评估后续IBD治疗与新发癌症(复发或新发)的关系。中位随访71个月,42例(20%)出现新发癌症,其中34例为乳腺癌复发。未治疗组调整发病率10.2/1000人年,暴露组28.9/1000人年(P=0.0519),无癌症生存率无显著差异(P=0.4796)。结论:除已知乳腺癌不良预后因素外,未发现IBD治疗显著增加新发乳腺癌风险。

要点

  • 有乳腺癌病史的IBD患者中,20%(42/207)出现新发癌症,其中34例为乳腺癌复发。
  • 未治疗组调整发病率10.2/1000人年,暴露组28.9/1000人年(P=0.0519)。
  • 治疗组与对照组无癌症生存率无显著差异(P=0.4796)。

核心结论

  • 除已知的乳腺癌不良预后因素外,未发现IBD治疗与新发乳腺癌风险存在统计学显著增加。

研究设计与样本

  • 多中心回顾性研究,纳入207例有乳腺癌病史的连续IBD患者,纳入日期为指数恶性肿瘤诊断日。
  • 随访从癌症诊断持续至新发癌症发生,中位随访71个月(四分位距34-148)。

主要发现

  • 207例患者中位病程13年(四分位距6-21),一线治疗中位间隔28个月(四分位距7-64)。
  • 一线治疗中传统免疫抑制剂占19.3%,抗肿瘤坏死因子占19.8%,维得利珠单抗占7.2%,乌司奴单抗占1.9%。
  • 随访期间共观察42例(20%)新发癌症,其中34例为乳腺癌复发。
  • 未治疗组调整发病率10.2/1000人年(95%CI 6.0-16.4),暴露组28.9/1000人年(95%CI 11.6-59.6),P=0.0519。
  • 治疗组与对照组无癌症生存率无显著差异(P=0.4796)。

关键数值与推荐

  • 多因素分析中与新发癌症相关的因素包括T4d分期(P=0.036)、三阴性肿瘤(P=0.016)和随访不足71个月(P=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence or new-onset cancer) in a cohort of patients with IBD with a history of breast cancer according to the subsequent IBD treatment provided. METHODS: A multicenter retrospective study included consecutive patients with IBD with prior breast cancer. The inclusion date corresponded to the diagnosis of index malignancy. Follow-up lasted from cancer diagnosis until the occurrence of incident cancer. RESULTS: Among 207 patients included (median disease duration, 13 years [interquartile range, 6-21]), first-line treatment (median interval of 28 months [interquartile range, 7-64]) was a conventional immunosuppressant in 19.3% of patients, anti-tumor necrosis factor in 19.8%, vedolizumab in 7.2%, and ustekinumab in 1.9%. After a median follow-up of 71 months (interquartile range, 34-148), 42 (20%) incident cancers were observed (34 breast cancer recurrences). Adjusted incidence rates per 1000 person-years were 10.2 (95% confidence interval, 6.0-16.4) for the untreated arm and 28.9 (95% confidence interval, 11.6-59.6) for exposed patients (P = .0519). There was no significant difference between treated patients and control subjects regarding incident cancer-free survival rates (P = .4796). In multivariable analysis, factors associated with incident cancer were stage T4d (P = .036), triple negative tumor (P = .016), and follow-up of less than 71 months (P = .005). CONCLUSIONS: We did not find a statistically significant increase in incident breast cancer related to IBD treatment beyond the already known poor prognostic factors of breast cancer.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, et al. Risk of Incident Cancer in Patients With Inflammatory Bowel Disease With Prior Breast Cancer: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 39505240. doi:10.1016/j.cgh.2024.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。